Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Arct | Mind Blowing Facts

Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies

Arcturus Therapeutics (NASDAQ:ARCT) President and CEO Joseph Payne outlined the company’s messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the Jefferies Global Healthcare Conference in New York. Payne described Arcturus as a “next generation messen

Cathie Wood Adds 48K Shares to This Under-the-Radar Growth Play

Cathie Wood Adds 48K Shares to This Under-the-Radar Growth Play

Wood trimmed stakes in Nvidia, Meta, and Tesla; instead, she added this speculative biotech play.

1 Under-$10 Stock Set to Surge as Much as 963% in 2026

1 Under-$10 Stock Set to Surge as Much as 963% in 2026

The high price estimate for Arcturus suggests the stock can rally as high as 963%. Is it a far-fetched target?

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stock was trading lower on Wednesday after the company shared interim results from its ongoing Phase 2 trial of ARCT-032, an investigational inhaled mRNA therapy for cystic fibrosis.

Intapp Posts Better-Than-Expected Earnings, Joins Sapiens International, Arcturus Therapeutics, Gildan Activewear And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Wednesday.

Mercury Systems Posts Better-Than-Expected Earnings, Joins Green Dot, Arcturus Therapeutics And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Tuesday.

Arcturus Therapeutics's Return On Capital Employed Overview

Benzinga Pro data, Arcturus Therapeutics (NASDAQ:ARCT) reported Q1 sales of $5.24 million. Earnings fell to a loss of $51.17 million, resulting in a 32.35% decrease from last quarter.

inkl

Read news from The Economist, FT, and more,
with one subscription

Expert Ratings for Arcturus Therapeutics

Expert Ratings for Arcturus Therapeutics

Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings:

Arcturus Therapeutics's Earnings Outlook

Arcturus Therapeutics's Earnings Outlook

Arcturus Therapeutics (NASDAQ:ARCT) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Arcturus Therapeutics will report an earnings per share (EPS) of $-1.44.

Arcturus' COVID-19 Vaccine Candidate Meets Primary Goal In Vietnam Study

Arcturus' COVID-19 Vaccine Candidate Meets Primary Goal In Vietnam Study

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) shared topline data from an ongoing Phase 1/2/3 trial evaluating the ARCT-154, a self-amplifying mRNA COVID-19 vaccine candidate. Results from the efficacy analysis have been submitted to the Vietnam Ministry of Health by Vinbiocare on April 13 and shared with Arcturus in parallel with this filing. The Phase…

Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx

Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx

Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical company" to run a clinical trial for LUNAR-COV19 vaccine candidate as a booster.

Arcturus Therapeutics's Return On Capital Employed Insights

Arcturus Therapeutics's Return On Capital Employed Insights

According to Benzinga Pro data, during Q4, Arcturus Therapeutics (NASDAQ:ARCT) posted sales of $5.79 million. Earnings were up 28.51%, but Arcturus Therapeutics still reported an overall loss of $38.66 million.

Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses

Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Mercury Systems

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

395,621 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play